Avmapki Fakzynja Co-Pack

Avmapki Fakzynja Co-Pack, a combination of avutometinib and defactinib are kinase inhibitor. This co-packaged medicine is used for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have previously been treated with systemic therapy.

Note: This indication is approved under accelerated approval based on tumor response rate (RR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Recommended Dosage:
Avmapki Capsules: The recommended dosage is 3.2 mg (four 0.8 mg capsules) taken orally twice weekly (Day 1 and Day 4) for the initial 3 weeks of each 4-week cycle until there is evidence of disease progression or unacceptable toxicity. Take this medicine at the same time with each dose. Take it with food. Swallow oral capsules whole. It is not advisable to chew, open, or break the capsules.

In case a dose is missed and it's been beyond 24 hours, just skip that dose. Take your next scheduled dose at the usual time. Never take two doses together to catch up for the skipped/missed one. In case of vomiting after taking Avmapki, avoid taking another dose. Just wait and take your next scheduled dose at the regular time.

Fakzynja Tablets: The recommended dosage is 200 mg (one tablet) taken orally twice daily for the initial 3 weeks of each 4-week cycle until there is evidence of disease progression or unacceptable toxicity. Take each dose with food. Swallow oral tablets whole. Do not break, chew, or crush the tablets.

In case a dose is missed by more than 6 hours, skip the missed dose and take the next scheduled dose as prescribed. Never take 2 tablets at the same time to catch up for a missed dose. In case you vomit after taking this therapeutic drug, avoid taking an additional dose. Take the next scheduled dose as prescribed.

• Treatment with Avutometinib 0.8 mg capsules can make your vision blurry, leave your eyes feeling dry, and even cause changes at the back of the eye. Doctors usually recommend a full eye check before starting the drug and repeat exams every few weeks. If you notice halos, floaters, or sudden brightness, let your healthcare team know right away; they may cut the dose or stop the medicine until the problem clears.
• Both agents can be responsible for causing serious dermatologic reactions, including exfoliative dermatitis, rash, or Stevens-Johnson syndrome. Monitor for skin changes, mainly during the first few cycles. Interrupt or stop treatment in case serious skin reactions occur and provide useful dermatologic care.
• Elevations in liver enzymes (ALT, AST) and bilirubin may occur. Monitor liver function tests before starting and regularly during treatment. Modify dose or discontinue in case of significant liver injury or persistent elevations, especially if accompanied by clinical symptoms.
• Avutometinib is associated with rhabdomyolysis and muscle toxicity. Monitor for weakness, muscle pain, and elevated creatine kinase (CK) levels. Stop treatment promptly in case rhabdomyolysis is confirmed, and start supportive care as clinically required.
  Avutometinib 0.8 mg capsules and defactinib 200 mg tablets may cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for a period after the final dose. Pregnancy status should be negative before starting treatment and counseling on potential reproductive risks.
• There is no information on the presence of avutometinib or defactinib in human milk. Because of the risk for side effects in infants, advise against breastfeeding during treatment and for a period after the final dose, as per clinical guidelines.
• Safety and effectiveness of avutometinib capsules and defactinib tablets co-packaging have not been established in pediatric patients. Use of this medicine in this population is not recommended unless clinical benefit outweighs potential risks and is supported by rigorous monitoring protocols.

What documents are required to import AVMAPKI FAKZYNJA CO-PACK to India?

AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) can be imported by patients or government hospitals in the name of the patients only.

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is AVMAPKI FAKZYNJA CO-PACK available in India?

AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Avmapki Fakzynja in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

AVMAPKI FAKZYNJA CO-PACK can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of AVMAPKI FAKZYNJA CO-PACK (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Avmapki 0.8 mg + Fakzynja 200 mg price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source AVMAPKI FAKZYNJA CO-PACK (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Avmapki Fakzynja Co-Pack®?

Avutometinib and defactinib is the Generic Name for the trade name drug Avmapki Fakzynja Co-Pack®.

What is the Manufacturer's Name of Avmapki Fakzynja Co-Pack®?

Avmapki Fakzynja Co-Pack® is manufactured by Verastem, Inc.

What is the dosage and form of Avmapki Fakzynja Co-Pack® supplied?

Avmapki Fakzynja Co-Pack is supplied in Capsules: 0.8 mg of avutometinib and Tablets: 200 mg of defactinib for oral administration.

What are the most common side effects of Avmapki 0.8 mg Capsules + Fakzynja 200 mg Tablets?

The most common side effects of Avmapki Fakzynja Co-Pack® are nausea, diarrhea, fatigue, rash, abdominal pain, pruritus, musculoskeletal pain, dry skin, edema, vomiting, dyspepsia, dermatitis acneiform, vitreoretinal disorders, visual impairment, constipation, dyspnea, cough, stomatitis, and urinary tract infection.

How much does Avmapki 0.8 mg Capsules + Fakzynja 200 mg Tablets cost in India?

Prices of Avmapki Fakzynja Co-Pack tablets may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Avmapki Fakzynja Co-Pack 0.8 mg + 200 mg cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Avmapki 0.8 mg Capsules + Fakzynja 200 mg Tablets be available in SAARC countries?

Apart from Gulf countries, Avmapki Fakzynja Co-Pack® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Avmapki + Fakzynja in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Avmapki 0.8 mg Capsules + Fakzynja 200 mg Tablets online in India?

Yes, one can buy Avmapki 0.8 mg + Fakzynja 200 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of this co-packaged medicine through legal channels.

What are the storage conditions of Avmapki 0.8 mg Capsules + Fakzynja 200 mg Tablets?

Store the capsules of Avmapki and tablets of Fakzynja refrigerated at 2 to 8°C (36 to 46°F) in their original bottles.